These findings highlight the need to evaluate TBK1 inhibitors, both in CC cell lines and in vivo models, to assess their applicability in counteracting YAP/TAZ-mediated immune suppression and HPV-induced tumorigenesis. The gene discussed is YAP1; the disease is cholangiocarcinoma.